Patents Examined by Michail A Belyavskyi
  • Patent number: 10443035
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 15, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Patent number: 10441610
    Abstract: Disclosed are methods and compositions of microbead carriers for delivery of cells and other biologically active substances to diseased or damaged tissue in a subject in need thereof.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: October 15, 2019
    Assignee: Georgia Tech Research Corporation
    Inventors: Barbara Dale Boyan, Zvi Schwartz, Christopher S. D. Lee, Shirae Kerisha Leslie, Ramsey C. Kinney
  • Patent number: 10428304
    Abstract: It is an object of the present invention to provide a method for easily producing an antigen-specific B cell population comprising IgG-positive B cells specific to a specific antigen. The present invention provides a method for producing a B cell population, comprising culturing B cells, in which the expression of a Bach2 gene has been increased, in the presence of a means for acting on CD40 and/or a BAFF receptor.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: October 1, 2019
    Assignees: TOKYO UNIVERSITY OF SCIENCE FOUNDATION, KANEKA CORPORATION
    Inventors: Daisuke Kitamura, Tomoyuki Nakaishi
  • Patent number: 10428312
    Abstract: An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fuc?1-2Gal?1-3GlcNAc1-3Gal?1 or Fuc?1-2Gal?1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: October 1, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Boon Hwa Andre Choo, Jiyun Zheng
  • Patent number: 10426795
    Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: October 1, 2019
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Patent number: 10420801
    Abstract: A method for suppressing an immune response is provided. The method involves administration of isolated lymphoid tissue-derived suppressive stromal cells (LSSC) to a subject in need of such treatment in an amount effective to suppress the immune response in the subject. The invention also involves a method to isolate LSSC by digesting lymphoid tissue fragments using a combination of an enzyme mix and agitation and then collecting the LSSC. Pharmaceutical preparations comprising LSSC are also provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 24, 2019
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Anne Fletcher, Shannon J. Turley, Biju Parekkadan
  • Patent number: 10420799
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: September 24, 2019
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10421946
    Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1bri. The perivascular mesenchymal precursor cell is multipotential and is shown to form, vascular tissue, as well as bone marrow dentin and pulp. A method of enriching using cell sorting based on these markers is also described.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: September 24, 2019
    Assignee: MESOBLAST, INC.
    Inventors: Stan Gronthos, Andrew Zannettino, Songtao Shi
  • Patent number: 10415016
    Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 17, 2019
    Assignee: POSEIDA THERAPEUTICS, INC.
    Inventors: Eric Ostertag, Devon Shedlock
  • Patent number: 10406178
    Abstract: In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes (“MILs”). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: September 10, 2019
    Assignee: The Johns Hopkins University
    Inventors: Ivan M. Borrello, Kimberly A. Noonan
  • Patent number: 10398734
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: September 3, 2019
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10383955
    Abstract: The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: August 20, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE NORMALE SUPERIEURE DE CACHAN, MEDIZINISCHE UNIVERSITAT WIEN
    Inventors: Michel Arock, Peter Valent, Rosine Saleh, Ghaith Wedeh, Christian Auclair
  • Patent number: 10385316
    Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 20, 2019
    Assignees: Baylor College of Medicine, Wilson Wolf Manufacturing
    Inventors: Ann Marie Leen, Ulrike Gerdemann, Cliona M. Rooney, Juan F. Vera Valdes, John R. Wilson
  • Patent number: 10377824
    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 13, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nils Lonberg, Mohan Srinivasan
  • Patent number: 10363273
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: July 30, 2019
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10364276
    Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: July 30, 2019
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Tsutomu Kanezaki, Shigeru Sakurai, Yukiko Noguchi, Mayumi Endo, Natsumi Hamabuchi, Kana Naito
  • Patent number: 10358495
    Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: July 23, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Erica Ullman, Aynur Hermann, Ella Ioffe, Elena Burova, Gavin Thurston
  • Patent number: 10350243
    Abstract: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 16, 2019
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Johannes L. Zakrzewski, Marcel R. m. Van Den Brink, Michel Sadelain
  • Patent number: 10351824
    Abstract: The present disclosure relates to a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: July 16, 2019
    Assignees: Cell Medica Limited, Baylor College of Medicine
    Inventors: Cliona M. Rooney, Ann M. Leen, Juan F. Vera, Minhtran V. Ngo, Rainer Ludwig Knaus
  • Patent number: 10344076
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 9, 2019
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker